| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands): Cost of goods sold is directly related to product sales only. Revenues derived from co promote revenue, which made up all of the Dermatology Product Sales in the first quarter had no cost of goods sold. As a result, cost of goods sold was only recorded in the three months ended June 30, 2016. | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Three Months Ended June 30, 2016 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | 982 | | $ | 1,248 | | $ | 2,230 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (1,998) | | | - | | | (1,998) | | | Research and development | | | - | | | (8,407) | | | (8,407) | | | General and administrative | | | - | | | (6,637) | | | (6,637) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (1,340) | | $ | (13,796) | | $ | (15,136) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Three Months Ended June 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | - | | $ | - | | | Direct cost of goods | | | - | | | - | | | - | | | Sales and marketing costs | | | (727) | | | - | | | (727) | | | Research and development | | | - | | | (3,959) | | | (3,959) | | | General and administrative | | | - | | | (3,076) | | | (3,076) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (727) | | $ | (7,035) | | $ | (7,762) | | | Segment assets | | $ | 1,569 | | $ | 82,130 | | $ | 83,699 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology | | | | | Six Months Ended June 30, 2016 | | Sales | | Product Development | | Consolidated | | | Net Revenue | | $ | 1,364 | | $ | 1,526 | | $ | 2,890 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (3,884) | | | - | | | (3,884) | | | Research and development | | | - | | | (16,244) | | | (16,244) | | | General and administrative | | | - | | | (12,665) | | | (12,665) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (2,844) | | $ | (27,383) | | $ | (30,227) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Six Months Ended June 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | 500 | | $ | 500 | | | Direct cost of goods | | | - | | | - | | $ | - | | | Sales and marketing costs | | | (1,300) | | | | | | (1,300) | | | Research and development | | | - | | | (13,053) | | | (13,053) | | | General and administrative | | | - | | | (5,980) | | | (5,980) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (1,300) | | $ | (18,533) | | $ | (19,833) | | | Segment assets | | $ | 1,569 | | $ | 82,130 | | $ | 83,699 | |
|